Clinical Trials Directory

Trials / Completed

CompletedNCT03900143

Safety, Efficacy and Usage Compliance of the Silk'n Tightra Device

Safety, Efficacy and Usage Compliance of the Silk'n Tightra Home Use Device for Improvement of Sexual Functioning, Vulvovaginal Appearance and Reduction of SUI.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Home Skinovations Ltd. · Industry
Sex
Female
Age
25 Years – 65 Years
Healthy volunteers
Accepted

Summary

This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n Tightra device for improvement of sexual functioning, vulvovaginal appearance and reduction of SUI.

Detailed description

This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n Tightra device. The study includes 12 treatment sessions 3 times a week, over a period of 4 weeks. Each subject will serve as her own control, while comparing results before and after treatment. Treatment will be performed on the internal volva for 20 min according to the device instructions, . Subjects that are interested in improving their labial appearance, and are willing to perform the external treatment twice a week in addition to the internal treatments, will be offered to conduct both treatments. The study will include one follow-up visit conducted one month following treatment end. During the second month of the study subjects will perform mainte-nance treatments and will gradually reduce the frequency of the treat-ments as follows: * Week 5: 2 treatments * Weeks 6-8: 1 treatment per week.

Conditions

Interventions

TypeNameDescription
DEVICETightra vaginal deviceVaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.

Timeline

Start date
2019-01-28
Primary completion
2019-03-25
Completion
2019-03-25
First posted
2019-04-02
Last updated
2019-05-07

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT03900143. Inclusion in this directory is not an endorsement.